Basel, Switzerland, July 7, 2026. Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026 in London, running July 12 through July 15. The data span Roche’s pharmaceutical and diagnostics divisions and reflect the company’s work developing next-generation medicines and diagnostic tools aimed at slowing, stopping, or preventing disease progression.
Roche will deliver 18 oral and poster presentations at the conference. The highlights include five oral presentations within a dedicated trontinemab Featured Research Session, an invited Perspectives Session on neuroimmune targets including NLRP3 for neurodegenerative diseases, and multiple presentations on the Elecsys pTau217 and pTau181 blood tests.
“We aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer’s patients through earlier detection and intervention,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our presentations at AAIC will feature data from our expanding Alzheimer’s disease portfolio, including investigational trontinemab, neuroinflammatory approaches and blood-based diagnostics.”
Matt Sause, CEO of Roche Diagnostics, pointed to the recent approval of Elecsys pTau217 as a milestone for accessible diagnosis. “With the approval of Elecsys pTau217, our third Alzheimer’s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,” Sause said. “For too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer’s disease.”
Pharmaceuticals
Trontinemab Featured Research Session
A 90-minute Featured Research Session will present five oral talks on trontinemab, Roche’s investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody. Presenters will share new long-term safety, amyloid removal, and biomarker data from the Phase Ib/IIa Brainshuttle AD open-label extension study. Modelling drawn from this study informed the dosing regimen now used in the ongoing Phase III TRONTIER 1 and TRONTIER 2 studies in early symptomatic Alzheimer’s disease.
Roche will also share, for the first time, the design of PrevenTRON, a Phase III study investigating trontinemab in preclinical Alzheimer’s disease. The study plans to recruit cognitively unimpaired individuals at high risk of progressing to symptomatic Alzheimer’s. Investigators will use Roche’s Elecsys pTau217 blood test to help identify potential participants.
NLRP3 Inhibition: Invited Perspectives Session
Roche is investigating multiple therapeutic approaches beyond amyloid targeting to address the complexity of neurodegenerative disease. AAIC invited Roche to present a Perspectives Session on the NLRP3 inflammasome in Alzheimer’s disease. The session will cover emerging preclinical and clinical data on the immunomodulatory effects of NLRP3 inhibition in neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease.
Diagnostics
Roche’s Elecsys pTau217 blood test recently received CE mark certification as both a rule-in and rule-out test for amyloid pathology in Alzheimer’s diagnosis. New data will be presented on the test’s performance in both primary and secondary care settings.
Additional data on the approved Elecsys pTau181 blood test, used for ruling out Alzheimer’s disease, will examine sample stability under different storage conditions and test performance across large, diverse, cognitively impaired patient populations. These findings support broader implementation of the test in routine clinical practice.
Roche will sponsor a symposium titled “Closing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer’s Disease Diagnosis” on Sunday, July 12, from 12:30 to 13:45 BST at the Crowne Plaza London Docklands Hotel. The symposium will address the growing role of blood-based biomarkers in early detection and diagnosis, including scalable testing approaches designed to reduce diagnostic barriers, identify at-risk individuals earlier, and expand access to disease-modifying therapies.
Key Presentations
Trontinemab
- Long-Term Safety and Amyloid Removal with Trontinemab: Interim Data from the Open-Label Extension of the Phase Ib/IIa Brainshuttle AD Study – Featured Research Session, Tuesday, July 14, 14:00–15:30 BST, Room S8
- Interim Long-Term Biomarker Results from the Trontinemab Open-Label Extension of the Phase Ib/IIa Brainshuttle AD Study
- Simulation of Amyloid Clearance in Phase III Studies with Trontinemab in Early Symptomatic Alzheimer’s Disease
- Evidence Supporting Preclinical AD as an Optimal Stage for Intervention with Trontinemab
- PrevenTRON: Rationale and Design of a Phase III Trial of Trontinemab in Cognitively Unimpaired Individuals with Biomarkers of Alzheimer’s Disease at High Risk of Clinical Decline
NLRP3
- The Role of NLRP3 in Alzheimer’s Disease: Reverse Translational Data from GRADUATE Phase III Trials – Perspectives Session, Tuesday, July 14, 14:00–15:30 BST, Room N11A
- Investigating the Role of the NLRP3 Inflammasome in the Pathogenesis of Alzheimer’s Disease – Poster #0274, Tuesday, July 14, 7:30–16:15 BST, Exhibit Hall
Clinical Insights
- External Controls Vs. Observed Placebo: How Close Can We Get? GRADUATE I and II Results – Featured Research Session, Monday, July 13, 9:00–10:30 BST, Room N10
- Tau Pathology Interferes with Amyloid Removal by Gantenerumab – Featured Research Session, Wednesday, July 15, 14:00–15:30 BST, Room Victoria 5/6
Diagnostics
- Rule-Out Performance of a Plasma pTau181 Immunoassay at Established Cutoffs in Subgroups Across a Large, Diverse, Cognitively Impaired Population – Featured Research Session, Wednesday, July 15, 14:00–15:30 BST, Room Victoria 5/6
- Evaluating a Future In Vitro Diagnostic pTau217 Plasma Assay for the Detection of Amyloid Pathology in Primary and Secondary Care Settings – Poster #1076, Sunday, July 12, 7:30–16:15 BST, Exhibit Hall
- Elecsys pTau181 Plasma Immunoassay Performance Against Centiloid-Based Amyloid Classification Across Clinical Stages – Poster #1071, Sunday, July 12, 7:30–16:15 BST, Exhibit Hall
- Elecsys Cerebrospinal Fluid Biomarker Ratio Concordance with Amyloid-Positron Emission Tomography in a Chinese Population – Poster #1070, Sunday, July 12, 7:30–16:15 BST, Exhibit Hall
- Sample Stability for a New pTau181 Plasma Immunoassay: Implications for Rule-Out Testing for Alzheimer’s Disease in Routine Clinical Practice – Poster #0476, Wednesday, July 15, 7:30–16:15 BST, Exhibit Hall
About Roche in Alzheimer’s
Roche has conducted scientific research in Alzheimer’s disease for more than two decades, working toward earlier detection, diagnosis, monitoring, and treatment that can slow, stop, or prevent disease progression.
The company’s Alzheimer’s portfolio includes investigational medicines targeting different disease types and stages, among them trontinemab, nivegacetor, and RG6627.
On the diagnostics side, Roche’s portfolio covers approved and investigational digital and blood-based tests and cerebrospinal fluid assays, including Elecsys pTau181, pTau217, and ApoE4.
Roche partners with clinicians, scientists, patient advocates, policymakers, and health systems to help translate research advances into benefits for people affected by Alzheimer’s disease worldwide.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company focused on preventing, stopping, and curing disease through science and technology spanning diagnostics, medicines, and digital solutions.
Founded in Basel, Switzerland, in 1896, Roche now provides medicines and diagnostics to patients in more than 150 countries. Across its Diagnostics and Pharmaceutical divisions, the company works in oncology, neurology, cardiovascular and metabolic disease, ophthalmology, infectious disease, and immunology.
Genentech, based in the United States, operates as a wholly owned subsidiary of the Roche Group. Roche also holds a majority stake in Chugai Pharmaceutical, a leading innovator in Japan’s therapeutic antibody market.
